Earnings
In its year-end financial report, Johnson & Johnson (J&J) predicted product sales for 2019 to range from $80.4 billion to $81.2 billion, about $1 to $2 billion below what Wall Street analysts projected. The company thinks this will largely be due to increased biosimilar competition.
Adocia confirmed its financial calendar for 2019 with a change in date of the annual shareholder’s meeting.
The growing edentulous population is expected to be an important factor driving the growth of the global dental biomaterials market throughout the forecast period as people aged 60 years and above are at a high risk of developing dental disorders
MDxHealth SA today issued a preliminary update on its 2018 financial results.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
Top-line readout of pivotal FORT Study in PKAN expected 3Q19
Lonza today is publishing unaudited Full-Year 2017 information excluding the Water Care business and taking into consideration additional reporting-related items to enable comparison and inform capital market participants about the upcoming reporting changes prior to our Full-Year 2018 results publication.
Promore Pharma AB today announced that the company’s partner and third largest shareholder PharmaResearch Products Ltd (PRP) has chosen to exercise the call option granted by the other main shareholders Midroc New Technology AB (Midroc) and Rosetta Capital IV Sarl (Rosetta) in May 2017.
The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2019 third quarter cash dividend of $0.50 per ordinary share, representing a 9 percent increase over the prior year.
Probiodrug AG today announces its third quarter business update for the period ending September 30, 2018.
PRESS RELEASES